Terms: = Thyroid cancer AND RARA, RAR, 5914, ENSG00000131759, NR1B1 AND Treatment
23 results:
1. Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas.
Warda A; Staniszewski LJP; Sabir Z; Livingston S; Sausedo M; Reshi S; Ron E; Applegate MT; Haddad D; Khamisi M; Marshall PA; Wagner CE; Jurutka PW
Cells; 2023 Nov; 12(21):. PubMed ID: 37947652
[TBL] [Abstract] [Full Text] [Related]
2. Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks.
Gulfidan G; Soylu M; Demirel D; Erdonmez HBC; Beklen H; Ozbek Sarica P; Arga KY; Turanli B
Arch Biochem Biophys; 2022 Jan; 715():109085. PubMed ID: 34800440
[TBL] [Abstract] [Full Text] [Related]
3. Fertility in female cancer survivors: a systematic review and meta-analysis.
Busnelli A; Vitagliano A; Mensi L; Acerboni S; Bulfoni A; Filippi F; Somigliana E
Reprod Biomed Online; 2020 Jul; 41(1):96-112. PubMed ID: 32456969
[TBL] [Abstract] [Full Text] [Related]
4. Targeting the vitamin D endocrine system (VDES) for the management of inflammatory and malignant skin diseases: An historical view and outlook.
Reichrath J; Zouboulis CC; Vogt T; Holick MF
Rev Endocr Metab Disord; 2016 Sep; 17(3):405-417. PubMed ID: 27447175
[TBL] [Abstract] [Full Text] [Related]
5. Steroid receptor RNA activator: Biologic function and role in disease.
Liu C; Wu HT; Zhu N; Shi YN; Liu Z; Ao BX; Liao DF; Zheng XL; Qin L
Clin Chim Acta; 2016 Aug; 459():137-146. PubMed ID: 27282881
[TBL] [Abstract] [Full Text] [Related]
6. Modulation of RXR function through ligand design.
Pérez E; Bourguet W; Gronemeyer H; de Lera AR
Biochim Biophys Acta; 2012 Jan; 1821(1):57-69. PubMed ID: 21515403
[TBL] [Abstract] [Full Text] [Related]
7. Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells.
Ohashi E; Kogai T; Kagechika H; Brent GA
Cancer Res; 2009 Apr; 69(8):3443-50. PubMed ID: 19351850
[TBL] [Abstract] [Full Text] [Related]
8. Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment.
Miasaki FY; Vivaldi A; Ciampi R; Agate L; Collecchi P; Capodanno A; Pinchera A; Elisei R
J Endocrinol Invest; 2008 Aug; 31(8):724-30. PubMed ID: 18852534
[TBL] [Abstract] [Full Text] [Related]
9. Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma.
Liu YY; Stokkel MP; Morreau HA; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2008 Apr; 68(4):605-9. PubMed ID: 17986279
[TBL] [Abstract] [Full Text] [Related]
10. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells.
Cras A; Darsin-Bettinger D; Balitrand N; Cassinat B; Soulié A; Toubert ME; Delva L; Chomienne C
Oncogene; 2007 Jun; 26(27):4018-24. PubMed ID: 17213810
[TBL] [Abstract] [Full Text] [Related]
11. Establishment and characterization of cell lines from three human thyroid carcinomas: responses to all-trans-retinoic acid and mutations in the BRAF gene.
Koh CS; Ku JL; Park SY; Kim KH; Choi JS; Kim IJ; Park JH; Oh SK; Chung JK; Lee JH; Kim WH; Kim CW; Cho BY; Park JG
Mol Cell Endocrinol; 2007 Jan; 264(1-2):118-27. PubMed ID: 17134824
[TBL] [Abstract] [Full Text] [Related]
12. Down-regulation of the tumor suppressor gene retinoic acid receptor beta2 through the phosphoinositide 3-kinase/Akt signaling pathway.
Lefebvre B; Brand C; Flajollet S; Lefebvre P
Mol Endocrinol; 2006 Sep; 20(9):2109-21. PubMed ID: 16613989
[TBL] [Abstract] [Full Text] [Related]
13. All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes.
Elisei R; Vivaldi A; Agate L; Ciampi R; Molinaro E; Piampiani P; Romei C; Faviana P; Basolo F; Miccoli P; Capodanno A; Collecchi P; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2005 Apr; 90(4):2403-11. PubMed ID: 15623821
[TBL] [Abstract] [Full Text] [Related]
14. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids.
Haugen BR; Larson LL; Pugazhenthi U; Hays WR; Klopper JP; Kramer CA; Sharma V
J Clin Endocrinol Metab; 2004 Jan; 89(1):272-80. PubMed ID: 14715861
[TBL] [Abstract] [Full Text] [Related]
15. Effect of ligands of nuclear hormone receptors on sodium/iodide symporter expression and activity in breast cancer cells.
Tanosaki S; Ikezoe T; Heaney A; Said JW; Dan K; Akashi M; Koeffler HP
Breast Cancer Res Treat; 2003 Jun; 79(3):335-45. PubMed ID: 12846418
[TBL] [Abstract] [Full Text] [Related]
16. Involvement of nuclear steroid/thyroid/retinoid receptors and of protein kinases in the regulation of growth and of c-erbB and retinoic acid receptor expression in MCF-7 breast cancer cells.
Schneider SM; Offterdinger M; Huber H; Grunt TW
Breast Cancer Res Treat; 1999 Nov; 58(2):171-81. PubMed ID: 10674883
[TBL] [Abstract] [Full Text] [Related]
17. Therapeutic applications for ligands of retinoid receptors.
Thacher SM; Vasudevan J; Chandraratna RA
Curr Pharm Des; 2000 Jan; 6(1):25-58. PubMed ID: 10637371
[TBL] [Abstract] [Full Text] [Related]
18. Related case report: in vivo suppression of thyrotropin by 9-cis retinoic acid.
Dabon-Almirante CL; Damle S; Wadler S; Hupart K
Cancer J Sci Am; 1999; 5(3):171-3. PubMed ID: 10367174
[TBL] [Abstract] [Full Text] [Related]
19. Negative feedback control of the retinoid-retinoic acid/retinoid X receptor pathway by the human TR4 orphan receptor, a member of the steroid receptor superfamily.
Lee YF; Young WJ; Burbach JP; Chang C
J Biol Chem; 1998 May; 273(22):13437-43. PubMed ID: 9593676
[TBL] [Abstract] [Full Text] [Related]
20. Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation.
Labelle Y; Zucman J; Stenman G; Kindblom LG; Knight J; Turc-Carel C; Dockhorn-Dworniczak B; Mandahl N; Desmaze C; Peter M
Hum Mol Genet; 1995 Dec; 4(12):2219-26. PubMed ID: 8634690
[TBL] [Abstract] [Full Text] [Related]
[Next]
